Patients treated

2000-2005

Patients treated

2009-2012

All patients

Statins users

Metformin users

Statins and Metformin users

Number of patients

302

79

381

146

27

12

Age [years]

74.3 ± 5.6

74.9 ± 7

74.4 ± 6.0

74.4 ± 6.0

72.2 ± 6.9

71.0 ± 8.3

Follow up time (median) [months]

91

[6 - 138]

26

[3 - 54]

70

[3 - 138]

69.8

[3 - 136]

62

[3 - 129]

45

[3 - 128]

Prostate Volume (mean) [cc]

78.9 ± 32.0

75.3 ± 26.6

78.0 ± 30.7

78.0 ± 30.8

91.4 ± 32

77.0 ± 14

Baseline PSA (mean)

9.1 ± 8.0

8.6 ± 6.7

9.0 ± 7.0

7.0 ± 4.8

5.4 ± 2.1

5.3 ± 1.6

Baseline PSA (median)

7.0

6.7

6.8

6.1

5.3

5.2

Diabetes

11%

(N = 33)

14%

(N = 14)

11.7%

(N = 47)

13%

(N = 19)

100%

(N = 27)

100%

(N = 12)

Hormonal Therapy [%]

35%

(N = 107)

42%

(N = 46)

40%

(N = 153)

33%

(N = 98)

32%

(N = 9)

8.3%

(N = 1)

Gleason > 6 [%]

56%

(N = 169)

67%

(N = 53)

58%

(N = 222)

56%

(N = 82)

37%

(N = 10)

67%

(N = 8)

Gleason = 8 - 10 [%]

17.9%

(N = 54)

16.5%

(N = 13)

18%

(N = 67)

16%

(N = 23)

15%

(N = 4)

0%

(N = 0)

T stage > T2a [%]

25.8%

(N = 78)

43%

(N = 34)

29%

(N = 112)

27%

(N = 39)

18.5%

(N = 5)

0%

(N = 0)

Biochemical Failure

19.7%

(N = 59)

7.6%

(N = 6)

17%

(N = 65)

14%

(N = 20)

15.4%

(N = 4)

0%

(N = 0)

Local Failure

3.3%

(N = 10)

2.5%

(N = 2)

3%

(N = 12)

3.5%

(N = 5)

3.7%

(N = 1)

0%

(N = 0)

Distant Failure

5.7%

(N = 17)

5.1%

(N = 4)

5.5%

(N = 21)

3.5%

(N = 5)

3.7%

(N = 1)

0%

(N = 0)

Died of Prostate Cancer

4.3%

(N = 13)

1%

(N = 1)

3.5%

(N = 14)

2.7%

(N = 4)

0%

(N = 0)

0%

(N = 0)

Died of Any Cause

24%

(N = 72)

7.5%

(N = 6)

21%

(N = 79)

16%

(N = 24)

19%

(N = 5)

8%

(N = 1)

Treatment Technique

5 field IMRT

7 field IMRT

Dose Prescription

Median Dose 75.6Gy in 1.8 Gy fractions

Median dose 80.3 Gy in 1.8 Gy fractions